Differences in mutations across tumour sizes in clear‐cell renal cell carcinoma

Steven M. Monda,Benjamin W. Carney,Allison M. May,Shuchi Gulati,Simpa S. Salami,Thenappan Chandrasekar,Evan T. Keller,Nicolai A. Huebner,Ganesh S. Palapattu,Marc A. Dall'Era
DOI: https://doi.org/10.1111/bju.16527
2024-09-14
BJU International
Abstract:Objective To assess the distribution of key mutations across tumour sizes in clear‐cell renal cell carcinoma (ccRCC), and secondarily to examine the prognostic impact of aggressive mutations in smaller ccRCCs. Patient and Methods The distribution of mutations (VHL, PBRM1, SETD2, BAP1 and CDKN2A loss) across tumour sizes was assessed in 1039 ccRCCs treated with nephrectomy in cohorts obtained from the Tracking Cancer Evolution (TRACERx), The Cancer Genome Atlas (TCGA) and the Cancer Genomics of the Kidney (CAGEKID) projects. Logistic regression was used to model the presence of each mutation against size. In our secondary analysis, we assessed a subset of ccRCCs ≤7 cm for associations of key aggressive mutations (SETD2, BAP1, and CDKN2A loss) with metastasis, invasive disease and overall survival, while controlling for size. A subset of localised tumours ≤7 cm was also used to assess associations with recurrence after nephrectomy. Results On logistic regression, each 1‐cm increase in tumour size was associated with aggressive mutations, SETD2, BAP1, and CDKN2A loss, at odds ratios (ORs) of 1.09, 1.10 and 1.19 (P
urology & nephrology
What problem does this paper attempt to address?